Supported by: Flanders Welcome Team Life Sciences
|
|
|
- Dale Perkins
- 5 years ago
- Views:
Transcription
1
2 Supported by: Flanders Welcome Team Life Sciences
3 5 essential key ingredients Smart financing Innovation ecosystem Expertise to build and connect Talent Strategic location with a global reach
4 Flanders combines all these ingredients Smart Financing Expertise Location Ecosystem Talent
5 #1 - SMART FINANCING
6 Tailored to life sciences needs Early stage PRIVATE Pre-seed and early stage capital PUBLIC Government grants up to 80% Mid stage PRIVATE VCs invest in sustainable growth PUBLIC Government support up to 80% Late stage Exits Introduction of international VCs Successful IPOs, M&A, #1 - SMART CAPITAL
7 #2 INNOVATION ECOSYSTEM
8 From idea to market Universities Academic Hospitals Research centers Bioincubators Pharma Biotech companies #2 INNOVATION ECOSYSTEM
9 Strongly developed life sciences industry 254 organizations > 100 additional technology providers > indirect jobs > direct jobs Companies are active in healthcare, agro and biobased applications with R&D activities with production activities dedicated competence providers #2 INNOVATION ECOSYSTEM
10 Biopharma concentration is unique Within 1 hour drive Janssen Pharmaceutica (Johnson & Johnson), Pfizer, GSK vaccines, UCB, Roche Diagnostics, Novartis, Sanofi, Large R&D centers in addition to HQs and manufacturing facilities #2 INNOVATION ECOSYSTEM
11 Home to one of the biggest Ag-Bio clusters worldwide Initiated by Prof. Van Montagu and Plant Genetic Systems, the first Agbiotech company worlwide Flanders is now home to Syngenta, Bayer and BASF with strong embedded R&D centers Fruitful collaborations with local academic centers enhance R&Dinvestments and result in new spin-offs, e.g. agrosavfe #2 INNOVATION ECOSYSTEM
12 Emerging biobased industry Government and industry invest in innovation and building expertise Bio Base Europe Europe s first education and open innovation center for the biobased economy Partnership Flanders building state-of-the-art research and pilot plant Netherlands training facilities #2 INNOVATION ECOSYSTEM
13 #3 EXPERTISE
14 From bench to patient Research Collaboration Biotech company Pharma
15 Flanders is European leader in number of clinical trials Belgium is a European leader for phase I and II clinical trials # trials Fastest approval in Europe (2 weeks) Flawless execution of complex trials #3 EXPERTISE
16 #4 TALENT
17 A hot spot for life sciences talent High quality managers, scientists and technicians Dedicated training Government support for training Supporting life sciences internships at industry Opinno project, FlandersBio MBI life sciences and health the Netherlands and Flanders VIB training: professional skills development - Project management, leadership Recycling entrepreneurs Management buy-out: Q-biologicals International recruiting Government grants support high profile recruiting Attractive region for international talent international schools, easy work permits for white collars #4 TALENT
18 Flemish people are highly motivated, dedicated workers Multilingual & efficient workers One of the highest productivity rates in the world #4 TALENT Source: The conference board, 2010
19 #5 - LOCATION
20 Embedded in a strong European Life sciences network Germany France UK: London Oxford Cambridge Switzerland Belgium - Wallonia #5 LOCATION
21 Flanders is a great place to live Excellence of living Renowned wining and dining Traveling throughout Europe is easy and fast London 1.5 hrs Eurostar Paris 1.20 hrs TGV Geneva 1.10 hrs flight Berlin 1.25 hrs flight #5 LOCATION
22 Flanders, a vibrant life sciences hot spot
23 Flanders, a vibrant life sciences hot spot > 1 billion investment in life sciences R&D /year > 250 dedicated life sciences organizations > direct R&D jobs > indirect jobs The biopharmaceutical companies Signed > 9 billion worth of licensing deals since 2005 Cashed > 2 billion in milestone and R&D payments #5 LOCATION
24 For more information on the life sciences cluster contact FlandersBio Henk Joos Managing Director
25 For more information on tax incentives contact FIT Marc Van Gastel Head of Department Invest
26 For more information on R&D subsidies contact IWT Dirk Veelaert Advisor
27 For more information on the research community contact VIB Katrien Swerts Manager New Ventures
28
Flanders, a health(y) ecosystem.
Flanders, a health(y) ecosystem Kathleen.dhondt@ewi.vlaanderen.be FLANDERS: Key Figures 2017 Flanders: a high-income region with an open economy in the core of Europe Population: 6.50 million (= 57,5%
The Belgian pharmaceutical industry strengthens its leading European position. Belgian pharma figures 2015, in a European perspective
The Belgian pharmaceutical industry strengthens its leading European position Belgian pharma figures 2015, in a European perspective INTRODUCTION In 2015, Belgium continued to reinforce its leading position
BIOTECH IN FRANCE. key info in. points
BIOTECH IN FRANCE 10 key info in points 1 2 3 INSERM: EUROPE S #1 ACADEMIC BIOTECH RESEARCH INSTITUTE INSERM spearheads healthcare and medical research in France, filing more biotech patents with the European
Commercialising early stage agbiotechnology from academia: challenges and opportunities. Rupert Osborn CEO, IP Pragmatics Ltd March 2011
Commercialising early stage agbiotechnology from academia: challenges and opportunities Rupert Osborn CEO, IP Pragmatics Ltd March 2011 Overview Introduction to IP Pragmatics Agbiotechnology crop market
Develop YOUR business in Medicon Valley Dedicated to helping you develop your business, Medicon Valley offers:
MEDICON VALLEY / 2011 03 Develop YOUR business in Medicon Valley Dedicated to helping you develop your business, Medicon Valley offers: > A pool of highly qualified life-science university graduates and
THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 118 PATIENT GROUPS with an interest in RESPIRATORY CONDTIONS
THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 118 PATIENT GROUPS with an interest in RESPIRATORY CONDTIONS PUBLISHED OCTOBER 2016 [Question to respondents: Which companies have the best record
Welcome to the Ministry of Foreign Affairs
Welcome to the Ministry of Foreign Affairs indk@um.dk www.investindk.com National Experimental Therapy Partnership (NEXT) NEXT is a public-private partnership within clinical research offering a one stop
About the Healthcare Strategic Analysis Team Geographic specific reports: Global issue reports: 1. About This Report Chapter structure Executive
About the Healthcare Strategic Analysis Team Geographic specific reports: Global issue reports: 1. About This Report Chapter structure Executive summary Licensing trends overview Evolving trends in the
Investments in the Life Sciences
Investments in the Life Sciences where how why June 4 th, 2014 Horst Domdey History of the Munich Biotech Cluster 1984 Foundation of the Munich Gene Center 1989 1 st Munich biotech company 1996 Munich
Information session on the Biobank legislation in Belgium
EUROPEAN CENTRE FOR CLINICAL RESEARCH TRAINING Information session on the Biobank legislation in Belgium JUN 2018 19 JUN 2018 Brussels Agenda of the Session: 14h00-14h30 Registration 14h30-15h30 Introduction
Joint Statement on the Innovative Medicines Initiative
Joint Statement on the Innovative Medicines Initiative FOR IMMEDIATE RELEASE Brussels, 6 July 2010 The Innovative Medicines Joint Technology Initiative (IMI) was launched in May 2007. From the beginning,
Structure of the Presentation
Vitalization of Industry Through the Promotion of Knowledge Intensive New Firms The Case of German Biotechnology The Japan Institute for Labour Policy and Training, Tokyo, 26.3.24 Prof. Dr. Holger Ernst
Valuing Healthcare Biotechnology in Europe: EuropaBio s perspective
Valuing Healthcare Biotechnology in Europe: EuropaBio s perspective The healthcare biotechnology sector The healthcare biotechnology sector includes bioscience based enterprises, which create and deliver
HIGH-TECH INDUSTRIES BIOTECH IN FRANCE KEY INFO IN POINTS
HIGH-TECH INDUSTRIES BIOTECH IN FRANCE KEY INFO IN 10 POINTS 1 67 BILLION IN REVENUES The biotech-medtech industry accounted for around 330,000 direct and indirect jobs and 67 billion in sales in 2016
HR Officer/Administrator Ardagh Metal Packaging, Hjørring
Recruitment Brief and Success Profile Anne Louise Kinnerup 13 February 2017 CANDIDATE INFORMATION HR Officer/Administrator Ardagh Metal Packaging, Hjørring AUSTRALIA AUSTRIA BELGIUM BRAZIL CHINA DENMARK
European Biotech & Pharma Innovation Development Dr. Patrik Frei May 2014 Shanghai
European Biotech & Pharma Innovation Development Dr. Patrik Frei May 2014 Shanghai 1 Overview 1. Overview European Biotechs / Clusters 2. Trends in the Biotech & Pharma Venture Valuation: Independent assessment
Inaugural Fraunhofer Delaware Technology Summit
Inaugural Fraunhofer Delaware Technology Summit Energy and Life Sciences Solu
Phylogica. Harnessing Biodiversity for Peptide Therapies. Life Sciences Showcase, 23 August 2011 Nick Woolf: CFO & VP Corporate Development
Phylogica Harnessing Biodiversity for Peptide Therapies Life Sciences Showcase, 23 August 2011 Nick Woolf: CFO & VP Corporate Development Introduction Biotech company offering leading peptide drug discovery
Swiss Medtech - Europe Medtech Development Dr. Patrik Frei September 2014 Suzhou
Swiss Medtech - Europe Medtech Development Dr. Patrik Frei September 2014 Suzhou 1 Overview 1. Overview European Medtech Venture Valuation: Independent assessment and valuation of technology driven companies
Sector Seminars Program
Sector Seminars 29 March 2017 Healthcare Belgium and Denmark are facing many of the same challenges in healthcare and in both countries initiatives to transform the healthcare system are on the agenda.
Valuation and HealthTech in Asia Dr. Patrik Frei January 2017 San Francisco
Valuation and HealthTech in Asia Dr. Patrik Frei January 2017 San Francisco Overview Introduction to Valuation Valuation of a Company / Therapeutic Product Valuation in Asia / HealthTech Asia's healthcare
Employment in the biopharma industry grew almost 5 percent in 2014, the last full year for which we have data. This is the highest annual growth rate
Thank you, Mr. Chairman, and members of the committee. I m Sarah MacDonald, Executive Vice President at MassBio, the life sciences trade association now representing over 700 member organizations. First,
Vitalisation of Industry Through the Promotion of Knowledge Intensive New Firms The Case of German Biotechnology
Vitalisation of Industry Through the Promotion of Knowledge Intensive New Firms The Case of German Biotechnology The Japan Institute for Labour Policy and Training, Tokyo, 26.3.4 Holger Ernst and Nils
Update on the IMI2 Proposal to Build a Sustainable pan- European Paediatric Clinical Trials Network
Update on the IMI2 Proposal to Build a Sustainable pan- European Paediatric Clinical Trials Network William R Treem, M.D.;* Child Health Innovation and Leadership Department, Johnson and Johnson October
What is One Nucleus? Vision. Mission
One Nucleus What is One Nucleus? A membership organisation Funded by sponsorship, membership fees, events and projects Based in Cambridge and London but with global members Formed by merger of ERBI and
OCTIMET. Company Profile
OCTIMET Oncology NV (OCTIMET) is a privately held Belgian based life science company specialized in accelerating the development of oncology therapies by providing rapid clinical proof of concept through
Biopeople at a Glance
Biopeople at a Glance Future Directions in Regulatory Science Copenhagen 21 April 2016 Per Spindler, Director www.biopeople.dk Welcome to Biopeople Biopeople, Faculty of Health and Medical Sciences, University
EVOTEC REPORTS FIRST QUARTER 2018 RESULTS AND PROVIDES CORPORATE UPDATE
, 09 MAY 2018 EVOTEC REPORTS FIRST QUARTER 2018 RESULTS AND PROVIDES CORPORATE UPDATE 55% INCREASE IN GROUP REVENUES STRONG UNDERLYING OPERATIONAL PERFORMANCE WITH NEW BUSINESS MIX AFTER APTUIT ACQUISITION
Valuation of Biosimilar and Key Value Drivers Dr. Patrik Frei October 2015 Biosimilars Asia
Valuation of Biosimilar and Key Value Drivers Dr. Patrik Frei October 0 Biosimilars Asia Agenda Introduction Valuation of Biosimilar Key Value Driver / Conclusion Venture Valuation Independent assessment
THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 199 PATIENT GROUPS with an interest in RARE DISEASES
THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 199 PATIENT GROUPS with an interest in RARE DISEASES PUBLISHED MAY 2016 Dans notre domaine de maladies rares où des efforts ont été faits pour
A European Public-Private Partnership! in Healthcare! Michel Goldman, MD,PhD Executive Director
A European Public-Private Partnership! in Healthcare! Michel Goldman, MD,PhD Executive Director ITMAT 2010, 27 October 2010 EFPIA Member Companies Participating companies (September 2010):! Innovative
ICON plc Brendan Brennan CFO
ICON plc Brendan Brennan CFO Jefferies HealthCare Conference New York 6 TH June 2017 Forward Looking Statement Certain statements will be forward looking statements. Actual results may differ materially
INSTITUT PASTEUR INSTITUT PASTEUR IS A PRIVATE, NON PROFIT, INSTITUTE DEDICATED TO RESEARCH & PUBLIC HEALTH
www.pasteur.fr INSTITUT PASTEUR INSTITUT PASTEUR IS A PRIVATE, NON PROFIT, INSTITUTE DEDICATED TO RESEARCH & PUBLIC HEALTH INSTITUT PASTEUR Created in 1887 by Louis Pasteur 2,700 people working in Paris
The Innovative Medicines Initiative
The Innovative Medicines Initiative Innovative funding for biotechs & SMEs in Europe Pierre Meulien, IMI Executive Director BIO-Europe Conference, Copenhagen 06.11.2018 IMI Europe s partnership for health
A comparative analysis of seven world leading biotech clusters
June 2017 A comparative analysis of seven world leading biotech clusters English summary 1 Content 1. Background and approach... 2 1.1. Background... 2 1.2. Methodological approach... 2 1.3. Contributors...
Career Growth Areas in Physiology / Pharmacology
Career Growth Areas in Physiology / Pharmacology Magdalena Alonso-Galicia, PhD Pharmacology Department Forest Research Institute, Inc. Jersey City, NJ 1 Career Growth Areas in BioPharma n Pharmaceutical
EHR4CR DEPLOYING INNOVATIVE CLINICAL TRIAL SERVICES. Brecht Claerhout, Custodix NV on behalf of the EHR4CR Consortium
EHR4CR DEPLOYING INNOVATIVE CLINICAL TRIAL SERVICES Brecht Claerhout, Custodix NV on behalf of the EHR4CR Consortium Electronic Health Records for Clinical Research Re-use of EHR data for optimizing Clinical
basic business essentials of biotechnology
basic business essentials of biotechnology SIMS Executive course Module 1 June 29 - July 1, 2006 Co-directed with: Introduction Science and Innovation Management Studies (SIMS), is organized by the Barcelona
THE FUTURE OF HEALTH IS BEING INVENTED IN NANTES SAINT-NAZAIRE
JOIN A RICH ECOSYSTEM Atlanpole Science a Technology Park, European Business & Innovation Center, Regional Incubator for the Pays de la Loire. Atlanpole Biothérapies Competitiveness cluster with 30 members
Utrecht Region. A key role in the Netherlands pharma/ biotech industries. Why locate your pharma/ biotech company in the Utrecht Region?
Utrecht Region A key role in the Netherlands pharma/ biotech industries Why locate your pharma/ biotech company in the Utrecht Region? The pharmaceutical and biotech sectors in the region s life sciences
Pharmaceutical and Biotechnology Construction Sector Report - UK Analysis
Pharmaceutical and Biotechnology Construction Sector Report - UK 2016-2020 Analysis Published: 16/09/2016 / Number of Pages: 98 / Price: 795.00 Introduction and Overview The 3rd edition of the report'pharmaceutical
International Conference on Pharmacy and Pharmaceutical Sciences April 09-11, 2018, Dubai UAE
International Conference on Pharmacy and Pharmaceutical Sciences April 09-11, 2018, Dubai UAE EMAIL: pharmacy@citationsinternational.com VISIT OUR WEBSITE: https://www.citationsinternational.com/pharmacy-conference-2018#about
ADDRESS BY H.R.H. PRINCE PHILIPPE OF BELGIUM BIO CONVENTION WASHINGTON
ADDRESS BY H.R.H. PRINCE PHILIPPE OF BELGIUM BIO CONVENTION WASHINGTON Your Excellencies, In most innovative and high added-value industries, everything starts with an idea a dream even to find ways to
2017 Call for Proposals EDCTP-TDR Clinical Research and Development Fellowships
2017 Call for Proposals EDCTP-TDR Clinical Research and Development Fellowships Call Identifier: TMA2017IF The purpose of this Call for Proposals is to provide funding towards actions that aim to support
Pharma/Life Sciences Hiring and Compensation Trends
Pharma/Life Sciences Hiring and Compensation Trends New York Pharma Forum John McLean Managing Partner Practice Leader Global Life Sciences June 4, 2015 On the Agenda Human capital landscape Talents/skills
Fare clic per modificare lo stile del sottotitolo dello schema THE BIOTECH SECTOR IN ITALY AND LOMBARDY
Fare clic per modificare lo stile del sottotitolo dello schema THE BIOTECH SECTOR IN ITALY AND TABLE OF CONTENT 1. THE BIOTECH SECTOR IN ITALY 2. : A LAND OF OPPORTUNITIES 3. : BIOTECH FACTS AND FIGURES
LIFE SCIENCES IN 495/METROWEST: EXISTING IMPORTANCE & FUTURE POSSIBILITY
LIFE SCIENCES IN 495/METROWEST: EXISTING IMPORTANCE & FUTURE POSSIBILITY February 15, 2018 Special thanks to our event host: Definition of Life Science Any one of the branches of science concerned with
FEBRUARY 2015 D. Lee Spurgin, Jr., PhD
FEBRUARY 2015 D. Lee Spurgin, Jr., PhD Resources - Publications Little Advisor ICH-GCP, Investigational Site - English Little Advisor ISO 14155:2011, Sponsor Responsibilities - English Little Advisor ISO
Speech Nancy McKinstry Annual General Meeting of Shareholders 2008 April 22, 2008 Okura Hotel Amsterdam
Speech Nancy McKinstry Annual General Meeting of Shareholders 2008 April 22, 2008 Okura Hotel Amsterdam Welcome and good morning. It is a pleasure to be here today to share our 2007 results and provide
2015 Investor Meeting
2015 Investor Meeting New York City December 4, 2015 Safe Harbor Except for historical information, the matters discussed in this presentation may constitute forward-looking statements that involve risks
Company Report Daring to be different
Company Report 2010 Daring to be different Daring to be different Galapagos has continued to follow its own unique path and is now a leading international biotechnology company. In our 2010 report, we
Career in Biotechnology Industry. Novartis Biocamp Roadshow
Career in Biotechnology Industry Novartis Biocamp Roadshow What is biotechnology? Biotechnology, often referred to as biotech, is the application of biological research techniques to create new processes
Hannover, your first foothold for business expansion into Europe
Hannover, your first foothold for business expansion into Europe Hannover Clinical Trial Center & hannoverimpuls Support for entering the health care market 1 The Hannover Region features all important
Bioeconomy and Opportunities in the Bio-based Industry of Malaysia. Dr. Abdul Manaf Mohamad Radzi
Bioeconomy and Opportunities in the Bio-based Industry of Malaysia Dr. Abdul Manaf Mohamad Radzi Malaysia s Strategic Advantages in Bioeconomy Government with strong interest in the Bioeconomy sector Abundance
Helping unlock growth opportunities worldwide
Helping unlock growth opportunities worldwide A trusted partner for high-stakes decisions While scientific and technological advances fuel new business opportunities, the cost of bringing each new product
THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (SPANISH EDITION)
THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (SPANISH EDITION) Feedback from 108 Spanish patient groups PUBLISHED MAY 2016 Nuevos tratamientos con precios que impidan el acceso para
KEY TECHNOLOGY, INC. NASDAQ GM (KTEC)
KEY TECHNOLOGY, INC. NASDAQ GM (KTEC) Economic Development Advisory Committee March 28, 2017 1 KEY TECHNOLOGY, INC. PRESENTER: Jack Ehren President and CEO 2 An Introduction to Key Technology, Inc. 3 INTRODUCTION
Technology Transfer, Academic and Industry Cooperations
Technology Transfer, Academic and Industry Cooperations Jake Micallef PhD MBA COO ValiRx plc Visiting lecturer Simfonec Jake.micallef@valirx.com What do they want? Universities Money to fund research and
14 May Evotec Q1 2013: Driving Innovation Efficiency
14 May 2013 Evotec Q1 2013: Driving Innovation Efficiency STRONG STRATEGIC POSITION SUPPORTS ACTION PLAN 2016 - INNOVATION EFFICIENCY EVOTEC S DRUG DISCOVERY PLATFORM GENERATES GROWTH NEW HORMONE IDENTIFIED
The Innovative Medicines Initiative: Building new models of collaborative research across Europe
The Innovative Medicines Initiative: Building new models of collaborative research across Europe Elisabetta Vaudano IMI, Belgium www.imi.europa.eu What is IMI? An European Public-Private Partnership Focused
BIOTECH FINANCING SUMMARY October 2016
BIOTECH FINANCING SUMMARY October 2016 In September, we saw that the number of Biotech financing rounds in the (Therapeutics and ) slightly decreased in comparison to August 2016. However, the aggregate
Korn Ferry Hay Group & FlandersBio (Bio)Pharma Salary Survey 2017
Korn Ferry Hay Group & FlandersBio (Bio)Pharma Salary Survey 2017 Content 1 CONTEXT 3 2 APPROACH 6 3 OUTPUT 12 4 PROJECT TEAM 17 5 INVESTMENT FOR PARTICIPANTS 19 6 WHAT WE ASK FROM PARTICIPANTS 21 2016
Cadila Healthcare Limited
Company, Position & Person Profile Cadila Healthcare Limited 6/8/15 About Zydus Cadila Zydus Cadila is a fully integrated, global healthcare provider, with strengths all along the pharmaceutical value
S-BIOMEDIC. Company Profile
S-Biomedic is a Belgium based life science company exploring the unexploited cosmetic and therapeutic potential of the skin microbiome. The skin microbiome a habitat of billions of beneficial and harmful
March 17, 2018 Ranking the Experience of European Physicians Interactions With Pharma. by Tim van Tongeren with Dennis van Rooij and Carlos Capella
March 17, 2018 Ranking the Experience of European Physicians Interactions With Pharma by Tim van Tongeren with Dennis van Rooij and Carlos Capella Executive Summary Each year, the pharmaceutical industry
The North Carolina Biotechnology Center Response to NER Request February 8, 2011
The North Carolina Biotechnology Center Response to NER Request February 8, 2011 1. Overview of what your entity does: The Biotechnology Center drives biotech job creation by supporting life-science researchers,
Stem cell and cell therapeutics research in Lithuania. Bernardas Morkunas Head of Business Development
Stem cell and cell therapeutics research in Lithuania Bernardas Morkunas Head of Business Development Lithuanian biotech Biotechnology is considered as one of 2014-2020 Smart Specialisation priority fields
Innovative Science Affordable Medicine
Innovative Science Affordable Medicine H1 FY13 Results Presentation : Oct 31, 2012 www.biocon.com Overall Financial Performance H1 FY13 H1 FY12 % Growth Revenue 1,235 1,001 23% EBITDA 305 281 8% 25% 28%
Idorsia Company Profile
Idorsia Headquartered in Switzerland - a biotech-hub of Europe - Idorsia is specialized in the discovery and development of small molecules, to transform the horizon of therapeutic options. Idorsia has
Doing Business in Germany
Doing Business in Germany An Executive Summary of Strategic Success Factors Liverpool & Glasgow, September 2013 Stefan Peikert, AHP International GmbH & Co. KG Member of the AHP Group Berlin Münster Heidelberg
Brecht Vanlerberghe Head R&D Bio Base Europe Pilot Plant
Improving policies in support of shared pilot facilities to increase their impact on the Key Enabling Technology Industrial Biotech and the European Bio-economy Brecht Vanlerberghe Head R&D Bio Base Europe
May 14, 2014 CGI Announces Acquisition of BioServe India
Empowering Personalized Cancer Treatment May 14, 2014 CGI Announces Acquisition of BioServe India CGI and BioServe India Enter Into Acquisition Agreement On May 14 th, 2014 Cancer Genetics, Inc. and BioServe
February 25, 2019 (Monday) 8:30-16:30 Hrs BioPark Visit (Only for Invitees)
February 25, 2019 (Monday) 8:30-16:30 Hrs BioPark Visit (Only for Invitees) 18:00-19:30 Hrs Inauguration of the 16 th BioAsia Convention Presentation of Genome Valley Excellence Award 19:30-20:00 Hrs Inauguration
PANEL: The Resurgence of Manufacturing in Biomedical and Bio-pharma Manufacturing: Overcoming Trials and Tribulations
Driving Innovation and Technology in the Bio-pharma Supply Chain PANEL: The Resurgence of Manufacturing in Biomedical and Bio-pharma Manufacturing: Overcoming Trials and Tribulations Mike Prindiville,
Johan Christenson MD; PhD Partner Farmasidagene 2014 Oslo
Johan Christenson MD; PhD Partner Farmasidagene 2014 Oslo 1 HealthCap Focuses on Breakthrough Therapeutics Significant resource base Partners with profound sector experience Six MD PhD s Extensive network
LSE Health Market Access Academy April 2018, London September 2018, London
LSE Health Market Access Academy 9 13 April 2018, London 10 14 September 2018, London In cooperation with the Boston Consulting Group Market Access Roundtable LSE Health Market Access Academy 2 The London
www.nonstop-devices.com OFFICES: LUXEMBOURG ZUG LONDON PORTSMOUTH PRAGUE MUNICH Our own internal Quality Assurance function Continual professional development for all our employees, ensuring you liaise
Creation of a pan-european Paediatric Clinical Trials Network. Heidrun Hildebrand (Bayer) & William Treem (Janssen),
Creation of a pan-european Paediatric Clinical Trials Network Heidrun Hildebrand (Bayer) & William Treem (Janssen), 19.12.2016 IMI webinar Need for public-private collaboration Due to European Regulation,
BioWorld s PARTNER in FOCUS: Open Innovations: Moscow
BioWorld s PARTNER in FOCUS: Open Innovations: Moscow GLOBAL BIOPHARMA INDUSTRY SEES OPPORTUNITY IN RUSSIA Top executives from companies as diverse at Medtronic, Pfizer, EADS, Google, Sanofi Pasteur and
New Ways to Source Innovation in the Healthcare Industry In-licensing needs Oncology of Janssen/Johnson & Johnson Innovation
New Ways to Source Innovation in the Healthcare Industry In-licensing needs Oncology of Janssen/Johnson & Johnson Innovation Dr. Klaus Suwelack Johnson & Johnson Innovation, Janssen-Cilag Germany, Neuss
Disclaimer. 2
www.valirx.com 1 Disclaimer This Document comprises an institutional presentation (the Presentation ) which has been prepared by and is the sole responsibility of ValiRx plc (the Company ). The content
Bunsens, Beer and Bugs from Chemistry to Fermentation and Microbiology
Bunsens, Beer and Bugs from Chemistry to Fermentation and Microbiology Alison Arnold (alison.arnold@ingenza.com) Ingenza Ltd Roslin, Edinburgh, UK SCI, University of Strathclyde 31 st May 2016 S. Alison
ICON plc. 10th Jan Ciaran Murray CEO Steve Cutler CEO Designate. JP Morgan 35TH Annual Healthcare
ICON plc Ciaran Murray CEO Steve Cutler CEO Designate JP Morgan 35TH Annual Healthcare 10th Jan 2017 Forward Looking Statement Certain statements will be forward looking statements. Actual results may
Going from Strength to Strength
The Basel region life sciences cluster 2017 Going from Strength to Strength Initiative Life Sciences Cluster Region Basel 2 Editorial The Basel region is without doubt one of the leading life sciences
Strategy of Successful Alliance for Domestic Biopharma
Strategy of Successful Alliance for Domestic Biopharma November 14, 2005 Sukwoo (Jeffrey) Oh, J.D. President & CEO SMART Biosciences, Inc. & Managing Director Roberts Mitani, LLC 1 Common Biopharma Myths
France Pharma RepTrak 2017
France Pharma RepTrak 2017 The World s Most Reputable Pharmaceutical Companies in France Olivier Forlini, Director Reputation Institute France June 2017 1 Why Measure Reputation? The success of your company
NEWSFLASH 03. FASILIS update. FASILIS: Stimulating new business development in Human Health
NEWSFLASH 03 FASILIS: Stimulating new business development in Human Health FASILIS (Facility Sharing in Life Sciences) is an international pilot project creating transnational links between SMEs and a
THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (EUROPE EDITION)
THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (EUROPE EDITION) Feedback from 797 patient groups in Europe PUBLISHED APRIL 2016 The perception [of pharma] has changed in the last years,
PREVIEW. Benchmarking European Investigator Payments Industry Standard Research
PREVIEW Benchmarking European Investigator Payments Info@ISRreports.com 2014 Industry Standard Research www.isrreports.com Report Overview This report provides an analysis of Europe s clinical trial compensation
healthcare company, focused on patients needs SANOFI AT A GLANCE
healthcare company, focused on patients needs SANOFI AT A GLANCE SANOFI A DIVERSIFIED GLOBAL HEALTHCARE LEADER, FOCUSED ON PATIENT NEEDS health, enhance life and respond to the potential healthcare needs
Maximising Malaysia s Role in the Global Biopharmaceutical Value Chain
Maximising Malaysia s Role in the Global Biopharmaceutical Value Chain Martyn Postle Cambridge Healthcare & Biotech EU-Malaysia Biotechnology Business Partnership 2007 Malaysia intends to become a global
ETB funding initiative: Transnational R&D&I Cooperation of Biotech SMEs
ETB funding initiative: Transnational R&D&I Cooperation of Biotech SMEs www.eurotransbio.eu What is EuroTransBio? EuroTransBio (ETB) is an international funding initiative of European program owners and
CRO partner in Rx/CDx Co-Development
CRO partner in Rx/CDx Co-Development DEDICATED DIALOGUE A sponsored roundtable discussion published in Pharmaceutical Executive Two Covance executives discuss a CRO s role in supporting Companion Diagnostics
THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (NORDIC EDITION)
THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (NORDIC EDITION) Feedback from 147 Nordic patient groups PUBLISHED JUNE 2016 Syöpälääkkeiden kehitys on ollut hyvä, ja yhä useammat paranevat.
A French Biotechnology company dedicated to the development and production of human endocrine cell lines. Innovation In Healthcare April 2012
A French Biotechnology company dedicated to the development and production of human endocrine cell lines Innovation In Healthcare 16-17 April 2012 1 French Biotechnology company Founded in S2 2004 in Paris
A D V A N C I N G I N N O V A T I O N I N H E A L T H C A R E Partners Innovation Fund
A D V A N C I N G I N N O V A T I O N I N H E A L T H C A R E Partners Innovation Fund Partners HealthCare July 2017 P A R T N E R S I N N O V A T I O N F U N D In Brief Capitalization $165M fund $100
Collaborations between pharma industry and academia as drivers for innovations
Collaborations between pharma industry and academia as drivers for innovations Dr. Monika Lessl Director Alliance Management Global Drug Discovery Bayer Schering Pharma Berlin, Germany Deutsch - Brasilianische
Singapore offers attractive
Singapore Biotech Guide 2008/2009 Singapore s Biomedical Sciences Landscape companies with spin offs to Singapore, while BMRC takes the lead in coordinating and funding public sector and academic research,
CMC Strategy Forum Prague Enda Moran EBE Satellite Session, 06 May 2013
CMC Strategy Forum Prague 2013 Enda Moran EBE Satellite Session, 06 May 2013 European Biopharmaceutical Enterprises EBE s VISION: fostering innovation, and promote favorable business and regulatory conditions
INVEST IN CÔTE D AZUR
INVEST IN CÔTE D AZUR Smart Grid companies The European laboratory of research, experimentation and standardization in the Smart Grid industry CÔTE D AZUR AN ACTIVE NETWORK FOR YOUR GREEN BUSINESS INNOVATE